This study evaluated the impact of delayed insurance approval on outcomes in patients prescribed alternate doses of biologic therapy for the treatment of IBD. Researchers found that longer time to insurance approval of a higher biologic dosing regimen was associated with an increase in C-reactive protein, an inflammatory marker, in at least 45 days after the decision to escalate dose, suggesting the longer time to approval, the less likely to see an improvement in C-reactive protein.

This poster evaluates patient characteristics and 3-month outcomes in patients prescribed alternate-dose biologic therapy. Of 220 patients, one-third were previous/current smokers, and 40% had a psychiatric comorbidity. Median disease duration was 11 years (IQR 6-18), 46% previously underwent surgery.

This study evaluated access and affordability of HIV PrEP in patients seen at a multidisciplinary PrEP clinic. In this cohort of mostly commercially insured men, the majority were able to access PrEP with low out-of-pocket costs facilitated by manufacturer assistance. Although generalizability beyond this population is limited, these results contradict perceived financial barriers to PrEP access.

This study was among the first to evaluate patient outcomes to all-oral, sofosbuvir (SOF)-based, HCV therapies in a real world setting and assess the impact of a clinic-integrated specialty pharmacy on therapy completion. We found higher completion rates in patients filling through VSP (97%) compared to outside pharmacies (93%), and a 100% medication access rate.

The objective of this study was to identify factors associated with movement through the HCV CoC after referral to a multidisciplinary ID clinic to sustained virologic response (SVR), including both general and historically difficult to treat populations.

This multi-site study evaluated the effectiveness of a clinical pharmacist-driven HCV delivery model in an open system. With an overall sustained virologic response (SVR) rate of 95% (per protocol), the clinical pharmacist-driven HCV treatment model was found to be effective and comparable to other real-world studies with specialist, non-specialist, and non-hepatology providers.

In this ambispective cohort study of patients referred to an outpatient Infectious Diseases Clinic for chronic HCV, we found significant differences in patient demographics, drug interactions, and time to treat between HCV monoinfected and HIV/HCV coinfected patients. This study provides a broad, yet concise overview of the differences in caring for patients with and without HIV/HCV coinfection.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

This study found that integrating a pharmacist into clinic significantly shortened time from treatment decision to shipment for LDD drugs, partially overcoming access barriers. Additionally, access to LDDs was still slower than non-LDDs as they cannot be fully integrated into clinic workflow. The integrated specialty pharmacy program adds value to patient access and outperforms LDDs, challenging the value of LDD networks beyond medical economics.

In this initiative, we evaluated outcomes following prescription of specialty dermatology medications in biologic-naïve patients. Of the 28 prescriptions evaluated, median time to approval was 9 days, with delays resulting from the need for a pharmacist to ascertain clinical data such as disease severity and treatment history.